Second-quarter reported sales growth of 13.0 percent; comparable sales growth of 4.8 percent
Second-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.31
Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5%¹
Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58
Abbott returned $2.1 billion to shareholders in the second quarter in the form of dividends and share repurchases

ABBOTT PARK, Ill., July 16, 2026 /PRNewswire/ — Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2026.


Second-quarter sales increased 13.0 percent on a reported basis and 4.8 percent on a comparable basis.
Second-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31, which excludes specified items.
Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5%1.
Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58.
In April, Abbott completed enrollment in its TECTONIC U.S. pivotal trial. This trial is designed to evaluate Abbott’s investigational Coronary Intravascular Lithotripsy (IVL) System for treating severe calcification in coronary arteries prior to stent implantation.
In April, at the Heart Rhythm Society (HRS) conference, Abbott presented new late-breaking data from four clinical trials that demonstrated strong clinical outcomes across the company’s pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios.
In May, Abbott announced it secured CE Mark for Libre® Duo, the world’s first dual glucose-ketone biowearable sensor. By providing real-time visibility into glucose and ketone levels, this new technology helps optimize the management of diabetes by detecting rising ketone levels, which can lead to diabetic ketoacidosis, a serious health condition for people with diabetes.
In May, Abbott completed its submission to the U.S. Food and Drug Administration (FDA) seeking approval for the company’s Amulet™ 360 left atrial appendage (LAA) device.
In May, the American Cancer Society (ACS) issued updated colorectal cancer (CRC) screening guidelines that reaffirmed Cologuard® and Cologuard Plus® as preferred screening options for adults age 45 and older who are at average risk for CRC.

“Our second-quarter results reflect the momentum we are building,” said Robert B. Ford, chairman and chief executive officer, Abbott. “We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year.”

SECOND-QUARTER BUSINESS OVERVIEW

Comparable sales growth:

Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott’s Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates. 




Second Quarter 2026 Results (2Q26)



 


 


Sales 2Q26 ($ in millions)



Total Company



 

Nutrition



 

Diagnostics



 

Established

Pharmaceuticals



 

Medical Devices





U.S.



5,216



 

871



 

1,660



 

—



 

2,680





International



7,377



 

1,273



 

1,432



 

1,499



 

3,173





Total reported



12,593



 

2,144



 

3,092



 

1,499



 

5,853





 
 
 
 
 
 
 
 
 
 


% Change vs. 2Q25



 
 
 
 
 
 
 
 
 


U.S.



22.0



 

(9.0)



 

104.8



 

n/a



 

7.0





International



7.5



 

1.4



 

5.1



 

8.4



 

10.7





Total reported



13.0



 

(3.1)



 

42.3



 

8.4



 

9.0





Total reported excl. foreign exchange impact



12.2



 

(3.6)



 

41.3



 

8.7



 

7.9





Comparable sales growth



4.8



 

(3.6)



 

2.9



 

8.7



 

8.4





 
 
 
 
 
 
 
 
 
 


    U.S.



3.5



 

(9.0)



 

4.0



 

n/a



 

8.0





    International



5.8



 

0.6



 

1.6



 

8.7



 

8.7




 




First Half 2026 Results (1H26)



 


 
 


Sales 1H26 ($ in millions)



Total Company



 

Nutrition



 

Diagnostics



 

Established

Pharmaceuticals



 

Medical Devices





U.S.



9,490



 

1,715



 

2,565



 

—



 

5,203





International



14,267



 

2,446



 

2,707



 

2,925



 

6,189





Total reported



23,757



 

4,161



 

5,272



 

2,925



 

11,392





 
 
 
 
 
 
 
 
 
 


% Change vs. 1H25



 
 
 
 
 
 
 
 
 


U.S.



12.4



 

(10.3)



 

52.5



 

n/a



 

7.4





International



9.3



 

—



 

6.4



 

10.7



 

14.2





Total reported



10.5



 

(4.5)



 

24.7



 

10.7



 

11.0





Total reported excl. foreign exchange impact



8.2



 

(5.6)



 

22.4



 

8.9



 

8.0





Comparable sales growth



4.3



 

(5.6)



 

2.4



 

8.9



 

8.4





 
 
 
 
 
 
 
 
 
 


    U.S.



3.0



 

(10.3)



 

3.0



 

n/a



 

8.3





    International



5.3



 

(1.9)



 

1.6



 

8.9



 

8.5







Refer to table titled “Non-GAAP Revenue Reconciliation” for a reconciliation of comparable sales growth.




 




Nutrition





 


Second Quarter 2026 Results (2Q26)





 


Sales 2Q26 ($ in millions)



Total



 

Pediatric



 

Adult





U.S.



871



 

525



 

346





International



1,273



 

500



 

773





Total reported



2,144



 

1,025



 

1,119





 
 
 
 
 
 


% Change vs. 2Q25



 
 
 
 
 


U.S.



(9.0)



 

(10.7)



 

(6.4)





International



1.4



 

7.3



 

(2.0)





Total reported



(3.1)



 

(2.7)



 

(3.4)





Total reported excl. foreign exchange impact



(3.6)



 

(3.1)



 

(4.0)





Comparable sales growth



(3.6)



 

(3.1)



 

(4.0)





 
 
 
 
 
 


    U.S.



(9.0)



 

(10.7)



 

(6.4)





    International



0.6



 

6.4



 

(2.8)




Worldwide Nutrition sales decreased 3.1 percent on a reported basis and 3.6 percent on a comparable basis in the second quarter.

Results in the quarter reflect the impact of lower sales volumes compared to the prior year and the effect of strategic pricing actions implemented in the fourth quarter of 2025. These pricing actions, together with the launch of new products, are contributing to improving performance. Nutrition sales increased $127 million on a sequential basis compared to the first quarter of 2026. 




First Half 2026 Results (1H26)





 


Sales 1H26 ($ in millions)



Total



 

Pediatric



 

Adult





U.S.



1,715



 

1,036



 

679





International



2,446



 

942



 

1,504





Total reported



4,161



 

1,978



 

2,183





 
 
 
 
 
 


% Change vs. 1H25



 
 
 
 
 


U.S.



(10.3)



 

(11.9)



 

(7.8)





International



—



 

2.4



 

(1.5)





Total reported



(4.5)



 

(5.6)



 

(3.5)





Total reported excl. foreign exchange impact



(5.6)



 

(6.4)



 

(4.9)





Comparable sales growth



(5.6)



 

(6.4)



 

(4.9)





 
 
 
 
 
 


    U.S.



(10.3)



 

(11.9)



 

(7.8)





    International



(1.9)



 

0.7



 

(3.5)




 




Diagnostics*





 


Second Quarter 2026 Results (2Q26)





 


Sales 2Q26 ($ in millions)



Total



 

Core Laboratory



 

Cancer Diagnostics



 

Rapid/Molecular

Diagnostics





U.S.



1,660



 

377



 

890



 

393





International



1,432



 

1,041



 

29



 

362





Total reported



3,092



 

1,418



 

919



 

755





 
 
 
 
 
 
 
 


% Change vs. 2Q25



 
 
 
 
 
 
 


U.S.



104.8



 

7.5



 

n/a



 

(14.5)





International



5.1



 

3.4



 

n/a



 

2.0





Total reported



42.3



 

4.4



 

n/a



 

(7.3)





Total reported excl. foreign exchange impact



41.3



 

3.2



 

n/a



 

(8.0)





Comparable sales growth



2.9



 

3.2



 

13.3



 

(8.0)





 
 
 
 
 
 
 
 


    U.S.



4.0



 

7.5



 

13.3



 

(14.5)





    International



1.6



 

1.7



 

13.8



 

0.5




Worldwide Diagnostics sales increased 42.3 percent on a reported basis and 2.9 percent on a comparable basis in the second quarter.

Worldwide Core Laboratory Diagnostics results were driven by strong growth in the U.S. and Latin America.

Rapid and Molecular Diagnostics results reflect lower sales of respiratory virus tests compared to the prior year.

Cancer Diagnostics results were driven by mid-teens growth of Cologuard, which is benefiting from a growing base of both new and repeat users. Results in the quarter also reflect contributions to growth from the precision oncology and international businesses. 




First Half 2026 Results (1H26)





 


Sales 1H26 ($ in millions)



Total



 

Core Laboratory



 

Cancer Diagnostics



 

Rapid/Molecular

Diagnostics





U.S.



2,565



 

724



 

983



 

858





International



2,707



 

1,966



 

32



 

709





Total reported



5,272



 

2,690



 

1,015



 

1,567





 
 
 
 
 
 
 
 


% Change vs. 1H25



 
 
 
 
 
 
 


U.S.



52.5



 

6.0



 

n/a



 

(14.1)





International



6.4



 

6.1



 

n/a



 

2.4





Total reported



24.7



 

6.1



 

n/a



 

(7.4)





Total reported excl. foreign exchange impact



22.4



 

3.2



 

n/a



 

(8.8)





Comparable sales growth



2.4



 

3.2



 

13.3



 

(8.8)





 
 
 
 
 
 
 
 


    U.S.



3.0



 

6.0



 

13.2



 

(14.1)





    International



1.6



 

2.2



 

16.5



 

(1.1)







*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Abbott’s Cancer Diagnostics business.





 


Refer to table titled “Non-GAAP Revenue Reconciliation” for a reconciliation of comparable sales growth.




 




Established Pharmaceuticals





 


Second Quarter 2026 Results (2Q26)





 


Sales 2Q26 ($ in millions)



Total



 

Key Emerging

Markets



 

Other





U.S.



—



 

—



 

—





International



1,499



 

1,164



 

335





Total reported



1,499



 

1,164



 

335





 
 
 
 
 
 


% Change vs. 2Q25



 
 
 
 
 


U.S.



n/a



 

n/a



 

n/a





International



8.4



 

9.8



 

3.7





Total reported



8.4



 

9.8



 

3.7





Total reported excl. foreign exchange impact



8.7



 

10.7



 

2.1





Comparable sales growth



8.7



 

10.7



 

2.1





 
 
 
 
 
 


    U.S.



n/a



 

n/a



 

n/a





    International



8.7



 

10.7



 

2.1




Established Pharmaceuticals sales increased 8.4 percent on a reported basis and 8.7 percent on a comparable basis in the second quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Sales in these geographies increased 9.8 percent on a reported basis and 10.7 percent on a comparable basis, led by double-digit growth in several countries across the Latin America and Asia Pacific regions. 




First Half 2026 Results (1H26)





 


Sales 1H26 ($ in millions)



Total



 

Key Emerging

Markets



 

Other





U.S.



—



 

—



 

—





International



2,925



 

2,253



 

672





Total reported



2,925



 

2,253



 

672





 
 
 
 
 
 


% Change vs. 1H25



 
 
 
 
 


U.S.



n/a



 

n/a



 

n/a





International



10.7



 

11.3



 

8.6





Total reported



10.7



 

11.3



 

8.6





Total reported excl. foreign exchange impact



8.9



 

10.1



 

4.9





Comparable sales growth



8.9



 

10.1



 

4.9





 
 
 
 
 
 


    U.S.



n/a



 

n/a



 

n/a





    International



8.9



 

10.1



 

4.9




 




Medical Devices





 


Second Quarter 2026 Results (2Q26)





 


Sales 2Q26 ($ in millions)



Total



 

Rhythm

Management



 

Electro-

physiology*



 

Heart

Failure



 

Vascular



 

Structural

Heart*



 

Neuro-

modulation



 

Diabetes

Care





U.S.



2,680



 

377



 

420



 

313



 

294



 

225



 

189



 

862





International



3,173



 

366



 

441



 

88



 

509



 

372



 

71



 

1,326





Total reported



5,853



 

743



 

861



 

401



 

803



 

597



 

260



 

2,188





 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


% Change vs. 2Q25



 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


U.S.



7.0



 

10.7



 

15.9



 

10.9



 

3.9



 

(9.8)



 

(2.1)



 

8.6





International



10.7



 

10.0



 

12.3



 

3.0



 

7.5



 

12.1



 

14.7



 

11.7





Total reported



9.0



 

10.4



 

14.0



 

9.0



 

6.1



 

2.7



 

2.0



 

10.5





Total reported excl. foreign exchange impact



7.9



 

9.5



 

13.4



 

8.7



 

5.1



 

1.7



 

1.2



 

9.0





Comparable sales growth



8.4



 

9.5



 

13.4



 

8.7



 

5.1



 

5.7



 

1.2



 

9.0





 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


    U.S.



8.0



 

10.7



 

15.9



 

10.9



 

3.9



 

(0.9)



 

(2.1)



 

8.6





    International



8.7



 

8.3



 

11.1



 

1.3



 

5.8



 

10.2



 

11.3



 

9.2




Worldwide Medical Devices sales increased 9.0 percent on a reported basis and 8.4 percent on a comparable basis in the second quarter.

Sales growth in the quarter was led by low-teens growth in Electrophysiology and high-single-digit growth in Rhythm Management, Diabetes Care, and Heart Failure.

In Diabetes Care, sales of continuous glucose monitors grew 11.0 percent on a reported basis and 9.5 percent on a comparable basis. 




First Half 2026 Results (1H26)





 


Sales 1H26 ($ in millions)



Total



 

Rhythm

Management



 

Electro-

physiology*



 

Heart

Failure



 

Vascular



 

Structural

Heart*



 

Neuro-

modulation



 

Diabetes

Care





U.S.



5,203



 

716



 

798



 

605



 

585



 

449



 

366



 

1,684





International



6,189



 

711



 

851



 

185



 

995



 

726



 

137



 

2,584





Total reported



11,392



 

1,427



 

1,649



 

790



 

1,580



 

1,175



 

503



 

4,268





 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


% Change vs. 1H25



 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


U.S.



7.4



 

11.1



 

14.8



 

11.1



 

6.2



 

(9.6)



 

(0.7)



 

9.2





International



14.2



 

15.9



 

15.7



 

13.5



 

8.7



 

18.1



 

20.4



 

14.0





Total reported



11.0



 

13.4



 

15.3



 

11.7



 

7.7



 

5.7



 

4.3



 

12.1





Total reported excl. foreign exchange impact



8.0



 

10.9



 

13.0



 

10.4



 

5.0



 

2.6



 

2.6



 

8.2





Comparable sales growth



8.4



 

10.9



 

13.0



 

10.4



 

5.0



 

6.2



 

2.6



 

8.2





 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


    U.S.



8.3



 

11.1



 

14.8



 

11.1



 

6.2



 

(2.2)



 

(0.7)



 

9.2





    International



8.5



 

10.7



 

11.2



 

7.8



 

4.3



 

12.4



 

13.2



 

7.5







*Abbott’s Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the second quarter of 2025 and $101 million of sales in the first half of 2025 were moved from Structural Heart to Electrophysiology.





 


Refer to table titled “Non-GAAP Revenue Reconciliation” for a reconciliation of comparable sales growth.




Abbott’s Financial Guidance

Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%1.

Abbott projects full-year 2026 adjusted diluted earnings per share of $5.45 to $5.60.

Abbott projects third-quarter 2026 adjusted diluted earnings per share of $1.38 to $1.46.

Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott’s results in accordance with GAAP.

Abbott Declares 410th Consecutive Quarterly Dividend

On June 12, 2026, the board of directors of Abbott declared the company’s quarterly dividend of $0.63 per share. Abbott’s cash dividend is payable Aug. 17, 2026, to shareholders of record at the close of business on July 15, 2026.

Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

About Abbott:

Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 122,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube. 

Abbott will live-webcast its second-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.

— Private Securities Litigation Reform Act of 1995 —

A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott’s operations are discussed in Item 1A, “Risk Factors” in our Annual Report on Form 10-K for the year ended Dec. 31, 2025, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.


In 2025, total worldwide sales were $44.328 billion, which included U.S. sales of $17.126 billion and international sales of $27.202 billion, and Abbott’s Structural Heart business received $89 million of compensation payments as part of a multi-year agreement with a competitor. Also in 2025, total worldwide sales for Exact Sciences were $3.247 billion, which included U.S. sales of $3.145 billion and international sales of $102 million.




Abbott Laboratories and Subsidiaries


Condensed Consolidated Statement of Earnings


Second Quarter Ended June 30, 2026 and 2025


(in millions, except per share data)


(unaudited)



 


 
 


 

2Q26



 

2Q25



 

% Change



 


Net Sales



$12,593



 

$11,142



 

13.0



 


 
 
 
 
 
 
 


Cost of products sold, excluding amortization expense



5,325



 

4,854



 

9.7



 


Amortization of intangible assets



658



 

420



 

56.8



 


Research and development



892



 

725



 

22.9



 


Selling, general, and administrative



4,025



 

3,091



 

30.3



 


Total Operating Cost and Expenses



10,900



 

9,090



 

19.9



 


 
 
 
 
 
 
 


Operating Earnings



1,693



 

2,052



 

(17.5)



 


 
 
 
 
 
 
 


Interest expense, net



299



 

50



 

n/m



 


Net foreign exchange (gain) loss



4



 

(11)



 

n/m



 


Other (income) expense, net



(134)



 

(137)



 

(2.5)



 


Earnings before taxes



1,524



 

2,150



 

(29.1)



 


Taxes on Earnings



596



 

371



 

60.8



1)





 
 
 
 
 
 
 


Net Earnings



$928



 

$1,779



 

(47.8)



 


 
 
 
 
 
 
 


Net Earnings excluding Specified Items, as described below



$2,290



 

$2,213



 

3.5



2)





 
 
 
 
 
 
 


Diluted Earnings per Common Share



$0.53



 

$1.01



 

n/m



 


 
 
 
 
 
 
 


Diluted Earnings per Common Share, excluding Specified Items, as described below



$1.31



 

$1.26



 

4.0



2)





 
 
 
 
 
 
 


Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options



1,743



 

1,751



 
 
 




NOTES:



 


See table titled “Non-GAAP Reconciliation of Financial Information” for an explanation of certain non-GAAP financial information.



 


n/m = Percent change is not meaningful.



 


See footnotes on the following section.



 


 
 


1)



2026 Taxes on Earnings includes the recognition of approximately $110 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $240 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.



 


 
 
 


 

2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.



 


 
 
 


2)



2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.362 billion, or $0.78 per share, for intangible amortization, charges related to acquisitions, legal reserves, investment impairments, and other net expenses.



 


 
 
 


 

2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $434 million, or $0.25 per share, for intangible amortization, charges related to restructuring and cost reduction initiatives, and other net expenses.



 

 




Abbott Laboratories and Subsidiaries


Condensed Consolidated Statement of Earnings


First Half Ended June 30, 2026 and 2025


(in millions, except per share data)


(unaudited)



 


 
 


 

1H26



 

1H25



 

% Change



 


Net Sales



$23,757



 

$21,500



 

10.5



 


 
 
 
 
 
 
 


Cost of products sold, excluding amortization expense



10,215



 

9,322



 

9.6



 


Amortization of intangible assets



1,080



 

840



 

28.5



 


Research and development



1,659



 

1,441



 

15.1



 


Selling, general, and administrative



7,765



 

6,152



 

26.2



 


Total Operating Cost and Expenses



20,719



 

17,755



 

16.7



 


 
 
 
 
 
 
 


Operating Earnings



3,038



 

3,745



 

(18.9)



 


 
 
 
 
 
 
 


Interest expense, net



367



 

99



 

n/m



 


Net foreign exchange (gain) loss



(9)



 

(18)



 

n/m



 


Other (income) expense, net



(293)



 

(264)



 

10.6



 


Earnings before taxes



2,973



 

3,928



 

(24.3)



 


Taxes on earnings



968



 

824



 

17.5



1)





 
 
 
 
 
 
 


Net Earnings



$2,005



 

$3,104



 

n/m



 


 
 
 
 
 
 
 


Net Earnings excluding Specified Items, as described below



$4,312



 

$4,132



 

4.4



2)





 
 
 
 
 
 
 


Diluted Earnings per Common Share



$1.14



 

$1.77



 

n/m



 


 
 
 
 
 
 
 


Diluted Earnings per Common Share,


excluding Specified Items, as described below



$2.46



 

$2.35



 

4.7



2)





 
 
 
 
 
 
 


Average Number of Common Shares Outstanding


Plus Dilutive Common Stock Options



1,745



 

1,749



 
 
 




NOTES:





See table titled “Non-GAAP Reconciliation of Financial Information” for an explanation of certain non-GAAP financial information.





n/m = Percent change is not meaningful.





See footnotes on the following section.





 
 


1)



2026 Taxes on Earnings includes the recognition of approximately $60 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $440 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. 





 
 


 

2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit. 





 
 


2)



2026 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $2.307 billion, or $1.32 per share, for intangible amortization, charges related to acquisitions, legal reserves, investment impairments, restructuring, and other net expenses.





 
 


 

2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $1.028 billion, or $0.58 per share, for intangible amortization, charges related to investment impairments, charges related to restructuring and cost reduction initiatives, expenses associated with acquisitions, and other net expenses.




 




Abbott Laboratories and Subsidiaries


Non-GAAP Reconciliation of Financial Information


Second Quarter Ended June 30, 2026 and 2025


(in millions, except per share data)


(unaudited)





 


 

2Q26





 

As

Reported

(GAAP)



 

Specified

Items



 

As

Adjusted





 
 
 
 
 
 


Intangible Amortization



$      658



 

$     (658)



 

$        —





Gross Margin



6,610



 

697



 

7,307





R&D



892



 

(25)



 

867





SG&A



4,025



 

(428)



 

3,597





Other (income) expense, net



(134)



 

(27)



 

(161)





Earnings before taxes



1,524



 

1,177



 

2,701





Taxes on Earnings



596



 

(185)



 

411





Net Earnings



928



 

1,362



 

2,290





Diluted Earnings per Share



$     0.53



 

$      0.78



 

$      1.31




Specified items reflect intangible amortization expense of $658 million and other net expenses of $519 million associated with acquisitions, legal reserves, investment impairments, and other net expenses. See table titled “Details of Specified Items” for additional details regarding specified items.




 

2Q25





 

As

Reported

(GAAP)



 

Specified

Items



 

As

Adjusted





 
 
 
 
 
 


Intangible Amortization



$      420



 

$     (420)



 

$        —





Gross Margin



5,868



 

478



 

6,346





R&D



725



 

(20)



 

705





SG&A



3,091



 

(1)



 

3,090





Other (income) expense, net



(137)



 

(1)



 

(138)





Earnings before taxes



2,150



 

500



 

2,650





Taxes on Earnings



371



 

66



 

437





Net Earnings



1,779



 

434



 

2,213





Diluted Earnings per Share



$      1.01



 

$      0.25



 

$      1.26




Specified items reflect intangible amortization expense of $420 million and other net expenses of $80 million associated with restructuring actions, costs associated with acquisitions, and other net expenses. See table titled “Details of Specified Items” for additional details regarding specified items.




Abbott Laboratories and Subsidiaries


Non-GAAP Reconciliation of Financial Information


First Half Ended June 30, 2026 and 2025


(in millions, except per share data)


(unaudited)





 


 

1H26





 

As


Reported

(GAAP)



 

Specified

Items



 

As


Adjusted





 
 
 
 
 
 


Intangible Amortization



$    1,080



 

$   (1,080)



 

$        —





Gross Margin



12,462



 

1,129



 

13,591





R&D



1,659



 

(49)



 

1,610





SG&A



7,765



 

(901)



 

6,864





Other (income) expense, net



(293)



 

(34)



 

(327)





Earnings before taxes



2,973



 

2,113



 

5,086





Taxes on Earnings



968



 

(194)



 

774





Net Earnings



2,005



 

2,307



 

4,312





Diluted Earnings per Share



$      1.14



 

$      1.32



 

$     2.46




Specified items reflect intangible amortization expense of $1.080 billion and other net expenses of $1.033 billion associated with restructuring actions, acquisitions, legal reserves, investment impairments, and other net expenses. See table titled “Details of Specified Items” for additional details regarding specified items.




 

1H25





 

As


Reported

(GAAP)



 

Specified

Items



 

As


Adjusted





 
 
 
 
 
 


Intangible Amortization



$      840



 

$     (840)



 

$        —





Gross Margin



11,338



 

926



 

12,264





R&D



1,441



 

(47)



 

1,394





SG&A



6,152



 

(11)



 

6,141





Other (income) expense, net



(264)



 

(36)



 

(300)





Earnings before taxes



3,928



 

1,020



 

4,948





Taxes on Earnings



824



 

(8)



 

816





Net Earnings



3,104



 

1,028



 

4,132





Diluted Earnings per Share



$      1.77



 

$      0.58



 

$     2.35




Specified items reflect intangible amortization expense of $840 million and other net expenses of $180 million associated with restructuring actions, acquisitions, investment impairment charges, and other net expenses. See table titled “Details of Specified Items” for additional details regarding specified items.

A reconciliation of the second-quarter tax rates for 2026 and 2025 is shown below: 




 

2Q26



 


($ in millions)



Pre-Tax


Income



 

Taxes on


Earnings



 

Tax


Rate



 


As reported (GAAP)



$    1,524



 

$      596



 

39.1 %



1)





Specified items



1,177



 

(185)



 
 
 


Excluding specified items



$    2,701



 

$       411



 

15.2 %



 


 
 
 
 
 
 
 


 

2Q25



 


($ in millions)



Pre-Tax


Income



 

Taxes on


Earnings



 

Tax


Rate



 


As reported (GAAP)



$    2,150



 

$       371



 

17.3 %



2)





Specified items



500



 

66



 
 
 


Excluding specified items



$    2,650



 

$      437



 

16.5 %



 




1)



2026 Taxes on Earnings includes the recognition of approximately $110 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $240 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.





 
 


2)



2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.




A reconciliation of the year-to-date tax rates for 2026 and 2025 is shown below: 




 

1H26



 


($ in millions)



Pre-Tax


Income



 

Taxes on


Earnings



 

Tax


Rate



 


As reported (GAAP)



$    2,973



 

$      968



 

32.5 %



3)





Specified items



2,113



 

(194)



 
 
 


Excluding specified items



$    5,086



 

$      774



 

15.2 %



 


 
 
 
 
 
 
 


 

1H25



 


($ in millions)



Pre-Tax


Income



 

Taxes on


Earnings



 

Tax


Rate



 


As reported (GAAP)



$    3,928



 

$      824



 

21.0 %



4)





Specified items



1,020



 

(8)



 
 
 


Excluding specified items



$   4,948



 

$      816



 

16.5 %



 




3)



2026 Taxes on Earnings includes the recognition of approximately $60 million of net tax expense primarily as a result of the resolution of various tax positions related to prior years. 2026 Taxes on Earnings also includes approximately $440 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.





 
 


4)



2025 Taxes on Earnings includes the recognition of approximately $90 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.




 




Abbott Laboratories and Subsidiaries


Non-GAAP Revenue Reconciliation


Second Quarter Ended June 30, 2026 and 2025


($ in millions)


(unaudited)





 


 

2Q26



 

2Q25



 

% Change vs. 2Q25





 
 
 
 
 
 
 
 
 
 
 

Non-GAAP





 

Abbott

Reported



Foreign

exchange



Comparable

Revenue



 

Abbott

Reported



Impact of

acquisition (a)



Impact


of multi-year

agreement (b)



Comparable

Revenue



 

Reported



Comparable





Total Company



12,593



(86)



12,507



 

11,142



811



(22)



11,931



 

13.0



4.8





U.S.



5,216



—



5,216



 

4,276



786



(22)



5,040



 

22.0



3.5





Intl



7,377



(86)



7,291



 

6,866



25



—



6,891



 

7.5



5.8





 
 
 
 
 
 
 
 
 
 
 
 


Total Diagnostics



3,092



(22)



3,070



 

2,173



811



—



2,984



 

42.3



2.9





U.S.



1,660



—



1,660



 

811



786



—



1,597



 

104.8



4.0





Intl



1,432



(22)



1,410



 

1,362



25



—



1,387



 

5.1



1.6





 
 
 
 
 
 
 
 
 
 
 
 


Total Cancer Diagnostics



919



—



919



 

—



811



—



811



 

n/a



13.3





U.S.



890



—



890



 

—



786



—



786



 

n/a



13.3





Intl



29



—



29



 

—



25



—



25



 

n/a



13.8





 
 
 
 
 
 
 
 
 
 
 
 


Total Medical Devices



5,853



(57)



5,796



 

5,369



—



(22)



5,347



 

9.0



8.4





U.S.



2,680



—



2,680



 

2,503



—



(22)



2,481



 

7.0



8.0





Intl



3,173



(57)



3,116



 

2,866



—



—



2,866



 

10.7



8.7





 
 
 
 
 
 
 
 
 
 
 
 


Total Structural Heart*



597



(6)



591



 

581



—



(22)



559



 

2.7



5.7





U.S.



225



—



225



 

249



—



(22)



227



 

(9.8)



(0.9)





Intl



372



(6)



366



 

332



—



—



332



 

12.1



10.2







*



Abbott’s Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the second quarter of 2025 were moved from Structural Heart to Electrophysiology.





a)



The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.





b)



Reflects the impact of compensation payments that Abbott’s Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.




 




Abbott Laboratories and Subsidiaries


Non-GAAP Revenue Reconciliation


First Half Ended June 30, 2026 and 2025


($ in millions)


(unaudited)





 


 

1H26



 

1H25



 

% Change vs. 1H25





 
 
 
 
 
 
 
 
 
 
 
 
 

Non-GAAP





 

Abbott

Reported



Impact of

acquisition (a)



Impact


of multi-year

agreement (b)



Foreign

exchange



Comparable

Revenue



 

Abbott

Reported



Impact of

acquisition (a)



Impact


of multi-year

agreement (b)



Comparable

Revenue



 

Reported



Comparable





Total Company



23,757



706



(8)



(500)



23,955



 

21,500



1,518



(46)



22,972



 

10.5



4.3





U.S.



9,490



681



(8)



—



10,163



 

8,444



1,470



(46)



9,868



 

12.4



3.0





Intl



14,267



25



—



(500)



13,792



 

13,056



48



—



13,104



 

9.3



5.3





 
 
 
 
 
 
 
 
 
 
 
 
 
 


Total Diagnostics



5,272



706



—



(98)



5,880



 

4,227



1,518



—



5,745



 

24.7



2.4





U.S.



2,565



681



—



—



3,246



 

1,682



1,470



—



3,152



 

52.5



3.0





Intl



2,707



25



—



(98)



2,634



 

2,545



48



—



2,593



 

6.4



1.6





 
 
 
 
 
 
 
 
 
 
 
 
 
 


Total Cancer Diagnostics



1,015



706



—



(1)



1,720



 

—



1,518



—



1,518



 

n/a



13.3





U.S.



983



681



—



—



1,664



 

—



1,470



—



1,470



 

n/a



13.2





Intl



32



25



—



(1)



56



 

—



48



—



48



 

n/a



16.5





 
 
 
 
 
 
 
 
 
 
 
 
 
 


Total Medical Devices



11,392



—



(8)



(306)



11,078



 

10,264



—



(46)



10,218



 

11.0



8.4





U.S.



5,203



—



(8)



—



5,195



 

4,842



—



(46)



4,796



 

7.4



8.3





Intl



6,189



—



—



(306)



5,883



 

5,422



—



—



5,422



 

14.2



8.5





 
 
 
 
 
 
 
 
 
 
 
 
 
 


Total Structural Heart*



1,175



—



(8)



(35)



1,132



 

1,112



—



(46)



1,066



 

5.7



6.2





U.S.



449



—



(8)



—



441



 

497



—



(46)



451



 

(9.6)



(2.2)





Intl



726



—



—



(35)



691



 

615



—



—



615



 

18.1



12.4







*



Abbott’s Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $101 million of sales in the first half of 2025 were moved from Structural Heart to Electrophysiology.





a)



The adjustment includes historical sales for Exact Sciences prior to the acquisition date. Exact Sciences was acquired by Abbott on March 23, 2026.





b)



Reflects the impact of compensation payments that Abbott’s Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.




 




Abbott Laboratories and Subsidiaries


Details of Specified Items


Second Quarter Ended June 30, 2026


(in millions, except per share data)


(unaudited)





 


 

Acquisition or

Divestiture-

related (a)



 

Restructuring

and Cost

Reduction

Initiatives (b)



 

Intangible

Amortization



 

Other (c)



 

Total

Specifieds





Gross Margin



$           32



 

$               4



 

$         658



 

$            3



 

$         697





R&D



(10)



 

—



 

—



 

(15)



 

(25)





SG&A



(42)



 

(1)



 

—



 

(385)



 

(428)





Other (income) expense, net



1



 

(1)



 

—



 

(27)



 

(27)





Earnings before taxes



$           83



 

$               6



 

$         658



 

$         430



 

1,177





Taxes on Earnings (d)



 
 
 
 
 
 
 
 

(185)





Net Earnings



 
 
 
 
 
 
 
 

$        1,362





Diluted Earnings per Share



 
 
 
 
 
 
 
 

$        0.78







The table above provides additional details regarding the specified items described on table titled “Non-GAAP Reconciliation of Financial Information.”





 
 


a)



Acquisition-related expenses include integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions, including inventory step-up amortization.





 
 


b)



Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans.





 
 


c)



Other includes $385 million for legal reserves related to an agreed-in-principle settlement, subject to satisfaction of certain contingencies, as well as charges related to investment impairments and incremental costs to comply with the European Union’s Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.





 
 


d)



Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $240 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.




 




Abbott Laboratories and Subsidiaries


Details of Specified Items


Second Quarter Ended June 30, 2025


(in millions, except per share data)


(unaudited)





 


 

Acquisition or 

Divestiture-

related (a)



 

Restructuring

and Cost

Reduction

Initiatives (b)



 

Intangible

Amortization



 

Other (c)



 

Total

Specifieds





Gross Margin



$             1



 

$             55



 

$         420



 

$            2



 

$         478





R&D



—



 

(7)



 

—



 

(13)



 

(20)





SG&A



(3)



 

1



 

—



 

1



 

(1)





Other (income) expense, net



(1)



 

—



 

—



 

—



 

(1)





Earnings before taxes



$            5



 

$              61



 

$         420



 

$           14



 

500





Taxes on Earnings (d)



 
 
 
 
 
 
 
 

66





Net Earnings



 
 
 
 
 
 
 
 

$         434





Diluted Earnings per Share



 
 
 
 
 
 
 
 

$        0.25







The table above provides additional details regarding the specified items described on table titled “Non-GAAP Reconciliation of Financial Information.”





 
 


a)



Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses.





 
 


b)



Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.





 
 


c)



Other includes incremental costs to comply with the European Union’s Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.





 
 


d)



Reflects the net tax benefit associated with the specified items and the recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings includes approximately $100 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.




 




Abbott Laboratories and Subsidiaries


Details of Specified Items


First Half Ended June 30, 2026


(in millions, except per share data)


(unaudited)





 


 

Acquisition or

Divestiture-

related (a)



 

Restructuring

and Cost

Reduction

Initiatives (b)



 

Intangible

Amortization



 

Other (c)



 

Total

Specifieds





Gross Margin



$           34



 

$               11



 

$       1,080



 

$            4



 

$        1,129





R&D



(11)



 

(10)



 

—



 

(28)



 

(49)





SG&A



(486)



 

(34)



 

—



 

(381)



 

(901)





Other (income) expense, net



(1)



 

(3)



 

—



 

(30)



 

(34)





Earnings before taxes



$         532



 

$             58



 

$       1,080



 

$         443



 

2,113





Taxes on Earnings (d)



 
 
 
 
 
 
 
 

(194)





Net Earnings



 
 
 
 
 
 
 
 

$       2,307





Diluted Earnings per Share



 
 
 
 
 
 
 
 

$         1.32







The table above provides additional details regarding the specified items described on table titled “Non-GAAP Reconciliation of Financial Information.”





 
 


a)



Acquisition-related expenses include stock-based compensation recognized as expense from equity awards accelerated in connection with the Exact Sciences acquisition, integration costs that represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions, including inventory step-up amortization.





 
 


b)



Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans.





 
 


c)



Other includes $385 million for legal reserves related to an agreed-in-principle settlement, subject to satisfaction of certain contingencies, as well as charges related to investment impairments and incremental costs to comply with the European Union’s Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.





 
 


d)



Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $440 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.




 




 Abbott Laboratories and Subsidiaries


Details of Specified Items


First Half Ended June 30, 2025


(in millions, except per share data)


(unaudited)





 


 

Acquisition or

Divestiture-

related (a)



 

Restructuring

and Cost

Reduction

Initiatives (b)



 

Intangible

Amortization



 

Other (c)



 

Total

Specifieds





Gross Margin



$             1



 

$              81



 

$         840



 

$            4



 

$         926





R&D



(1)



 

(23)



 

—



 

(23)



 

(47)





SG&A



(6)



 

(6)



 

—



 

1



 

(11)





Other (income) expense, net



(25)



 

—



 

—



 

(11)



 

(36)





Earnings before taxes



$           33



 

$             110



 

$         840



 

$           37



 

1,020





Taxes on Earnings (d)



 
 
 
 
 
 
 
 

(8)





Net Earnings



 
 
 
 
 
 
 
 

$       1,028





Diluted Earnings per Share



 
 
 
 
 
 
 
 

$        0.58







The table above provides additional details regarding the specified items described on table titled “Non-GAAP Reconciliation of Financial Information.”





 
 


a)



Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.





 
 


b)



Restructuring and cost reduction initiative expenses include severance, outplacement, and other direct costs associated with specific restructuring plans and cost reduction initiatives.





 
 


c)



Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment impairments.





 
 


d)



Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings includes approximately $300 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.




 

SOURCE Abbott

For further information: Abbott Financial: Michael Comilla, 224-668-1872, Tamika McLoughlin, 224-399-5082, Randy Blakley, 224-668-0036, or Abbott Media: Karen Twigg May, 224-668-2681, Kate Dyer, 224-668-9965